Meptid (Meptazinol)

Meptazinol works by partially activating µ‑opioid receptors, which reduces the perception of pain while limiting the maximal effect that can cause respiratory depression. It also blocks κ‑opioid receptors, contributing to a more favorable safety profile compared with full µ‑agonists.

The specific dose of Meptid is determined by the prescribing clinician based on the patient’s pain intensity, clinical condition, and response to therapy. Healthcare professionals adjust the amount and frequency to achieve adequate analgesia while minimizing side effects.

Safety data for meptazinol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Meptid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Compared with full µ‑opioid agonists such as morphine, meptazinol offers analgesia with a lower ceiling effect on respiratory depression due to its partial agonist activity. This can result in a reduced risk of severe respiratory compromise, though efficacy may be slightly less for very intense pain.

Meptid should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the vial from direct sunlight, moisture and extreme temperatures. Do not freeze the solution, and keep it out of reach of children.

Meptid is supplied as an injectable solution for intramuscular or intravenous injection. Administration is performed by a qualified healthcare professional, who selects the appropriate route, dose and injection site based on the patient’s clinical needs.

The most serious risks include respiratory depression, severe hypotension, and rare anaphylactic reactions. Patients should be monitored for signs of shallow breathing, sudden drops in blood pressure, or allergic symptoms such as rash, swelling or difficulty breathing, especially after the first dose.

Meptid is contraindicated in patients with known hypersensitivity to meptazinol or any component of the formulation, in those with severe respiratory insufficiency, and in individuals taking monoamine oxidase inhibitors within the past 14 days. It should also be used with caution in patients with significant hepatic or renal impairment.